S M Swain1, A Schneeweiss2,3, L Gianni4, J J Gao5, A Stein6, M Waldron-Lynch7, S Heeson7, M S Beattie6, B Yoo8, J Cortes9,10, J Baselga11. 1. Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, USA. 2. National Center for Tumor Diseases, University Hospital Heidelberg, Germany. 3. Department of Gynecology and Obstetrics, University Hospital Heidelberg, Heidelberg, Germany. 4. Department of Medical Oncology, San Raffaele Hospital, Milan, Italy. 5. Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, MA, USA. 6. BioOncology, Genentech, Inc., South San Francisco, CA, USA. 7. Clinical Development, Roche Products Ltd, Welwyn Garden City, UK. 8. Biostatistics, Genentech, Inc., South San Francisco, CA, USA. 9. Ramon y Cajal University Hospital, Madrid, Spain. 10. Medical Oncology Department, Vall d'Hebron Institute of Oncology, Barcelona, Spain. 11. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
Abstract
Background: Pertuzumab disrupts heterodimerization between human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), HER3, and HER4. Thus, pertuzumab could result in adverse events similar to those observed with EGFR antagonists, such as diarrhea. We report the incidence and severity of diarrhea observed with pertuzumab in the CLEOPATRA, NeoSphere, and TRYPHAENA studies. Patients and methods: Patients (n = 1443) had metastatic [CLEOPATRA (n = 804)] or early-stage breast cancer [NeoSphere (n = 416) and TRYPHAENA (n = 223)]. The incidence and severity of diarrhea were analyzed by treatment received. The incidence of febrile neutropenia concurrent with diarrhea and the effect of pre-existing gastrointestinal comorbidities were also evaluated. Subgroup analyses were carried out using CLEOPATRA data. Results: The incidence of all-grade diarrhea across studies was generally greater for pertuzumab-based treatment, ranging from 28% to 72% (grade 1, 21%-54%; grade 2, 8%-37%; grade 3, 0%-12%; grade 4, 0%). Incidence was highest during the first pertuzumab-containing cycle, decreasing with subsequent cycles. Dose delays or discontinuations due to diarrhea were infrequent, ranging from 0% to 8%. Among pertuzumab-treated patients with diarrhea, 47%-67% received pharmacological intervention, most commonly with loperamide. Overlap between diarrhea and febrile neutropenia was uncommon, ranging from 0% to 11%. No relationship was observed between pre-existing gastrointestinal comorbidities and diarrhea. In CLEOPATRA, patients ≥65 years treated with pertuzumab had a higher incidence of grade 3 diarrhea than patients <65 years (19% versus 8%). All-grade diarrhea occurred at greater frequency among pertuzumab-treated Asian versus white patients with metastatic breast cancer (74% versus 63%); the corresponding rates in the control arm were 53% and 45%, respectively. Conclusions: In both the metastatic and early-stage breast cancer settings, diarrhea was common but manageable for all pertuzumab-containing regimens. Diarrheal episodes were mainly low grade and occurred most often during the first treatment cycle. Diarrheal-related drug delays or discontinuations were uncommon. ClinicalTrials.gov identifiers: NCT00567190 (CLEOPATRA), NCT00545688 (NeoSphere), NCT00976989 (TRYPHAENA).
Background: Pertuzumab disrupts heterodimerization between humanepidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), HER3, and HER4. Thus, pertuzumab could result in adverse events similar to those observed with EGFR antagonists, such as diarrhea. We report the incidence and severity of diarrhea observed with pertuzumab in the CLEOPATRA, NeoSphere, and TRYPHAENA studies. Patients and methods: Patients (n = 1443) had metastatic [CLEOPATRA (n = 804)] or early-stage breast cancer [NeoSphere (n = 416) and TRYPHAENA (n = 223)]. The incidence and severity of diarrhea were analyzed by treatment received. The incidence of febrile neutropenia concurrent with diarrhea and the effect of pre-existing gastrointestinal comorbidities were also evaluated. Subgroup analyses were carried out using CLEOPATRA data. Results: The incidence of all-grade diarrhea across studies was generally greater for pertuzumab-based treatment, ranging from 28% to 72% (grade 1, 21%-54%; grade 2, 8%-37%; grade 3, 0%-12%; grade 4, 0%). Incidence was highest during the first pertuzumab-containing cycle, decreasing with subsequent cycles. Dose delays or discontinuations due to diarrhea were infrequent, ranging from 0% to 8%. Among pertuzumab-treated patients with diarrhea, 47%-67% received pharmacological intervention, most commonly with loperamide. Overlap between diarrhea and febrile neutropenia was uncommon, ranging from 0% to 11%. No relationship was observed between pre-existing gastrointestinal comorbidities and diarrhea. In CLEOPATRA, patients ≥65 years treated with pertuzumab had a higher incidence of grade 3 diarrhea than patients <65 years (19% versus 8%). All-grade diarrhea occurred at greater frequency among pertuzumab-treated Asian versus white patients with metastatic breast cancer (74% versus 63%); the corresponding rates in the control arm were 53% and 45%, respectively. Conclusions: In both the metastatic and early-stage breast cancer settings, diarrhea was common but manageable for all pertuzumab-containing regimens. Diarrheal episodes were mainly low grade and occurred most often during the first treatment cycle. Diarrheal-related drug delays or discontinuations were uncommon. ClinicalTrials.gov identifiers: NCT00567190 (CLEOPATRA), NCT00545688 (NeoSphere), NCT00976989 (TRYPHAENA).
Authors: José Baselga; Javier Cortés; Sung-Bae Kim; Seock-Ah Im; Roberto Hegg; Young-Hyuck Im; Laslo Roman; José Luiz Pedrini; Tadeusz Pienkowski; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; Sandra M Swain Journal: N Engl J Med Date: 2011-12-07 Impact factor: 91.245
Authors: David B Agus; Robert W Akita; William D Fox; Gail D Lewis; Brian Higgins; Paul I Pisacane; Julie A Lofgren; Charles Tindell; Douglas P Evans; Krista Maiese; Howard I Scher; Mark X Sliwkowski Journal: Cancer Cell Date: 2002-08 Impact factor: 31.743
Authors: Sandra M Swain; Young-Hyuck Im; Seock-Ah Im; Valorie Chan; David Miles; Adam Knott; Emma Clark; Graham Ross; José Baselga Journal: Oncologist Date: 2014-05-28
Authors: A Schneeweiss; S Chia; T Hickish; V Harvey; A Eniu; R Hegg; C Tausch; J H Seo; Y-F Tsai; J Ratnayake; V McNally; G Ross; J Cortés Journal: Ann Oncol Date: 2013-05-22 Impact factor: 32.976
Authors: Matthew C Franklin; Kendall D Carey; Felix F Vajdos; Daniel J Leahy; Abraham M de Vos; Mark X Sliwkowski Journal: Cancer Cell Date: 2004-04 Impact factor: 31.743
Authors: R Califano; N Tariq; S Compton; D A Fitzgerald; C A Harwood; R Lal; J Lester; J McPhelim; C Mulatero; S Subramanian; A Thomas; N Thatcher; M Nicolson Journal: Drugs Date: 2015-08 Impact factor: 9.546
Authors: Charlotte I Stroes; Sandor Schokker; Aafke Creemers; Remco J Molenaar; Maarten C C M Hulshof; Stephanie O van der Woude; Roel J Bennink; Ron A A Mathôt; Kausilia K Krishnadath; Cornelis J A Punt; Rob H A Verhoeven; Martijn G H van Oijen; Geert-Jan Creemers; Grard A P Nieuwenhuijzen; Maurice J C van der Sangen; Laurens V Beerepoot; Joos Heisterkamp; Maartje Los; Marije Slingerland; Annemieke Cats; Geke A P Hospers; Maarten F Bijlsma; Mark I van Berge Henegouwen; Sybren L Meijer; Hanneke W M van Laarhoven Journal: J Clin Oncol Date: 2019-12-06 Impact factor: 44.544
Authors: Nicolas Martin; Nicolas Isambert; Carlos Gomez-Roca; Rainer-Georg Goeldner; Sylvie Zanetta; Behbood Sadrolhefazi; Hélène de Mont-Serrat; Mario Campone; Jean-Pierre Delord Journal: Cancer Chemother Pharmacol Date: 2018-10-22 Impact factor: 3.333
Authors: Olga Yankulina; Andrew R Zullo; Sarah E Cabral; Justin P Huynh; Jennifer A Hutchinson; Mary L Lopresti; Mary A Fenton; Christine M Berard-Collins Journal: J Oncol Pharm Pract Date: 2019-10-20 Impact factor: 1.809
Authors: Andreas Schneeweiss; Tjoung-Won Park-Simon; Joan Albanell; Ulrik Lassen; Javier Cortés; Veronique Dieras; Marcus May; Christoph Schindler; Frederik Marmé; Juan Miguel Cejalvo; Maria Martinez-Garcia; Iria Gonzalez; Jose Lopez-Martin; Anja Welt; Christelle Levy; Florence Joly; Francesca Michielin; Wolfgang Jacob; Céline Adessi; Annie Moisan; Georgina Meneses-Lorente; Tomas Racek; Ian James; Maurizio Ceppi; Max Hasmann; Martin Weisser; Andrés Cervantes Journal: Invest New Drugs Date: 2018-01-19 Impact factor: 3.850